We are live on ! Find out more
ROSG

Rosetta Genomics Ltd.
ROSG

Delisted

ROSG was delisted on the 21st of May, 2018.

Back to rankings

2 hedge funds and large institutions have $19K invested in Rosetta Genomics Ltd. in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 8 → 2 (-6)

97% less capital invested

Capital invested by funds: $552K → $19K (-$533K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

Holders
2
Holders Change
-6
Holders Change %
-75%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.86K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$160K
2
UBS Group
UBS Group
Switzerland
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$19K +$2.86K +7,085 +0.8%
Morgan Stanley
2
Morgan Stanley
New York
– -$160K -390,930 Closed
UBS Group
3
UBS Group
Switzerland
– -$6K -14,870 Closed

ROSG Hedge Fund Activity: Q2 2018 in Review

2 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q2 2018, worth a combined $19K — down 97% from $552K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ROSG and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Sabby Management, adding an estimated $2.86K. The largest seller was Morgan Stanley, exiting entirely with an estimated $160K sold.

  • 2 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q2 2018, down from 8 in Q1 2018.
  • Funds reported $19K of Rosetta Genomics Ltd. stock for Q2 2018, down 97% quarter-over-quarter.
  • 0 funds opened new Rosetta Genomics Ltd. positions in Q2 2018 and 6 closed out, a net change of -6 holders.
  • The largest Rosetta Genomics Ltd. buyer in Q2 2018 was Sabby Management, an estimated $2.86K added.
  • The largest Rosetta Genomics Ltd. seller in Q2 2018 was Morgan Stanley, an estimated $160K sold.

Based on aggregated 13F filings for Q2 2018.